1173 Multi-Institutional Assessment of Circulating Cell-Free DNA in CSF Facilitates CNS Lymphoma Diagnosis and Treatment Initiation

View at publisher Summarise with VIRAT
Authors: Briana C. Prager, Mihir Gupta, Timothy R. West, Christopher Michael Ramundo, Jack Bagin, Leonardo de Macêdo Filho, Nicholas Zeke Georgantas, Rachel H. Pilacky, Deborah Anne Forst, Justin T. Jordan, Alireza Mansouri, Bob S. Carter
+5 more Daniel P. Cahill, Brian Vala Nahed, Jorg Dietrich, Charlotte Wang, Ganesh M. Shankar
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

INTRODUCTION: Current standard-of-care for diagnosis of central nervous system (CNS) lymphoma typically requires biopsy, which risks neurologic morbidity and contributes to diagnostic delays. MYD88 L265P is a recurrent point mutation that is prevalent in CNS lymphoma. We have previously demonstrated that MYD88 L265P can be detected via PCR of cell-free DNA in the CSF of patients with CNS lymphoma. METHODS: We designed a rapid PCR assay to detect MYD88 L265P in cell-free DNA. The CLIA-certified lab test was implemented over 16 months in a prospective cohort across 184 patients at 19 hospitals. Diagnostic efficacy including sensitivity, specificity as well as clinical trajectories of tested patients were analyzed. RESULTS: 14 patients were positive for MYD88 L265P, all of whom were initiated on CNS lymphoma-targeted treatment with clinical response. PCR-based detection of MYD88 was 100% specific with respect to biopsy-proven CNS lymphoma and 42% sensitive. Adding MYD88 to standard-of-care CSF studies significantly increased the sensitivity and specificity of CSF sampling (p = 7.1 × 10-5), and the overall proportion of patients with a positive CSF assay for lymphoma increased from 45% to 79%. Multiple patients (N = 6) were started on treatment without CNS tissue biopsy. MYD88 positive results preceded biopsy results in 6/8 patients, and time-to-treatment was faster in patients who underwent CSF MYD88 L265P testing without CNS biopsy (p = 0.048). CONCLUSIONS: Rapid PCR for MYD88 L265P in cell-free DNA is an accurate, safe, rapid and minimally invasive diagnostic method for CNS lymphoma. Detection of MYD88 L265P variant in CSF led to timely initiation of appropriate and effective targeted treatment without requiring tissue biopsy.

Fields of Study & Subjects

CNS Lymphoma Diagnosis and Treatment Lymphoma Diagnosis and Treatment Viral-associated cancers and disorders

Publication details

Journal / source
Neurosurgery
Volume
72
Issue
Supplement_1
Pages
228–228
Publication date
26 March 2026
Language
EN